Actively Recruiting
Evaluating the Effects and Safety of Oral PIPE-791 Compared to Placebo in Adults with Idiopathic Pulmonary Fibrosis
Led by Contineum Therapeutics · Updated on 2026-11-04
324
Participants Needed
107
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the effects of PIPE-791 in adults aged 40 years and older with Idiopathic Pulmonary Fibrosis IPF, a lung disease characterized by progressive scarring. This Phase 2, randomized, double-blind, placebo-controlled global study aims to evaluate the efficacy, safety, tolerability, and how the body processes PIPE-791 in participants who may or may not be receiving other approved IPF treatments. The study is sponsored by Contineum Therapeutics and will enroll approximately 324 participants. Participants will be assigned to one of three groups two different daily oral doses of PIPE-791 or a placebo. The treatment period lasts 26 weeks. The full study duration extends up to 36 weeks, including screening before treatment and follow-up after treatment ends. Participants receive their assigned tablets daily during the treatment phase. Throughout the study, participants will undergo lung function tests such as forced vital capacity FVC, high-resolution CT scans to assess lung fibrosis, and safety monitoring for any side effects or adverse events. Researchers will track changes in lung function and overall health from the start of treatment to week 26, with additional safety follow-up until week 30. The study involves regular visits for assessments, and participant involvement may last up to 36 weeks in total.
CONDITIONS
Brief Title
Study to Evaluate the Efficacy, Safety, and Tolerability of PIPE 791 in Subjects With Idiopathic Pulmonary Fibrosis
Research Team
N
Nikki Nepomuceno
M
Marietta Franco
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here